Literature DB >> 34780033

Plasma aldosterone concentration is associated with white matter lesions in patients with primary aldosteronism.

Yujuan Yuan1,2, Nanfang Li3, Yan Liu4, Menghui Wang1, Mulalibieke Heizhati1, Qing Zhu1, Xiaoguang Yao1, Qin Luo1.   

Abstract

PURPOSE: Primary aldosteronism (PA) is the most frequent form of secondary hypertension. Hypertension is a risk factor for cognitive decline and dementia. White matter lesions (WMLs) are linked to vascular risk factors, which increase the risk of dementia. We aimed to analyze the association of PA-related parameters and WMLs in patients with PA.
METHODS: We conducted a retrospective analysis of all patients with PA in the Hypertension Center of the People's Hospital of Xinjiang Uygur Autonomous Region from January 1, 2011 to April 1, 2021. We analyzed the relationship between plasma aldosterone concentration (PAC), plasma renin activity (PRA), aldosterone-renin ratio (ARR), serum potassium, and WMLs.
RESULTS: We enrolled 138 patients with WMLs and matched these to controls without WMLs at a 1:4 ratio. Among the analytic sample (N = 711) with ages ranging from 30 to 64 years, 69% were male. In the logistic regression analysis, PAC, PRA and serum potassium were treated as continuous variables. The results showed that PAC (OR 1.04, 95% CI 1.01, 1.06, P = 0.008) was positively associated with the risk of WMLs, and serum potassium (OR 0.26, 95% CI 0.16, 0.44, P < 0.001) was inversely associated with the risk of WMLs. PRA (OR 0.86, 95% CI 0.68, 1.08, P = 0.384) was not associated with the risk of WMLs after adjusting for confounders. The results of restricted cubic splines showed the dose-response association between increasing PAC, ARR, decreasing serum potassium, and the risk of WMLs. We also divided PAC, ARR and serum potassium into two groups according to the result of restricted cubic splines. After adjusting for confounders, patients who were in Q2 (≥23.12 ng/dl) of PAC (OR 2.07, 95% CI 1.36, 3.15), Q2 (≥56.81 (ng/dl per ng/ml*h) of ARR (OR 1.82, 95% CI 1.22, 2.72) and Q2 (≤3.58 mmol/l) of serum potassium (OR 2.99, 95% CI 1.95, 4.50) had a significantly higher risk of WMLs than their counterparts. In stratified analyses, there was no evidence of subgroup heterogeneity regarding the change in the risk of WMLs (P > 0.05 for interaction for all).
CONCLUSION: Our results suggested that the PAC and serum potassium were related to the risk of WMLs in patients with PA. In particular, PAC ≥23.12 ng/dl significantly increased the risk of WMLs in patients with PA.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Aldosterone–renin ratio (ARR); Plasma aldosterone concentration (PAC); Primary aldosteronism (PA); Serum potassium; White matter lesions (WMLs)

Mesh:

Substances:

Year:  2021        PMID: 34780033     DOI: 10.1007/s12020-021-02920-w

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  44 in total

1.  Primary Aldosteronism: Present and Future.

Authors:  John W Funder
Journal:  Vitam Horm       Date:  2018-12-23       Impact factor: 3.421

Review 2.  Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.

Authors:  Silvia Monticone; Fabrizio D'Ascenzo; Claudio Moretti; Tracy Ann Williams; Franco Veglio; Fiorenzo Gaita; Paolo Mulatero
Journal:  Lancet Diabetes Endocrinol       Date:  2017-11-09       Impact factor: 32.069

3.  Primary Aldosteronism and Cardiovascular Events: It Is Time to Take Guideline Recommendations Seriously.

Authors:  Martin Reincke
Journal:  Hypertension       Date:  2018-01-22       Impact factor: 10.190

4.  Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension.

Authors:  Mirko Parasiliti-Caprino; Chiara Lopez; Nunzia Prencipe; Barbara Lucatello; Fabio Settanni; Giuseppe Giraudo; Denis Rossato; Giulio Mengozzi; Ezio Ghigo; Andrea Benso; Mauro Maccario
Journal:  J Hypertens       Date:  2020-09       Impact factor: 4.844

Review 5.  Mechanisms of mineralocorticoid action.

Authors:  Peter J Fuller; Morag J Young
Journal:  Hypertension       Date:  2005-11-14       Impact factor: 10.190

6.  Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice.

Authors:  Silvia Monticone; Jacopo Burrello; Davide Tizzani; Chiara Bertello; Andrea Viola; Fabrizio Buffolo; Luisa Gabetti; Giulio Mengozzi; Tracy A Williams; Franco Rabbia; Franco Veglio; Paolo Mulatero
Journal:  J Am Coll Cardiol       Date:  2017-04-11       Impact factor: 24.094

7.  The development of hypertension and hyperaldosteronism in a rodent model of life-long obesity.

Authors:  Carrie A Northcott; Greg D Fink; Hannah Garver; Joseph R Haywood; Erinn L Laimon-Thomson; Jonathon L McClain; Paulo W Pires; William E Rainey; Christine S Rigsby; Anne M Dorrance
Journal:  Endocrinology       Date:  2012-02-21       Impact factor: 4.736

8.  The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.

Authors:  John W Funder; Robert M Carey; Franco Mantero; M Hassan Murad; Martin Reincke; Hirotaka Shibata; Michael Stowasser; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2016-03-02       Impact factor: 5.958

9.  Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.

Authors:  Gregory L Hundemer; Gary C Curhan; Nicholas Yozamp; Molin Wang; Anand Vaidya
Journal:  Lancet Diabetes Endocrinol       Date:  2017-11-09       Impact factor: 32.069

10.  Long term outcome of Aldosteronism after target treatments.

Authors:  Vin-Cent Wu; Shuo-Meng Wang; Chia-Hui Chang; Ya-Hui Hu; Lian-Yu Lin; Yen-Hung Lin; Shih-Chieh Jeff Chueh; Likwang Chen; Kwan-Dun Wu
Journal:  Sci Rep       Date:  2016-09-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.